Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q1 2014-15 Earnings Presentation
26 slides from Alembic Pharmaceuticals's earnings presentation, June 2014
Slide 1: Investor Presentation
Alembic Pharmaceuticals Limited Investor Presentation June 2014 BSE: Symbol: ALEMPHARM Code: 533573 NSE: Symbol: APLLTD ISIN: INE901L01018 www.alembic-india.com
Slide 2: Safe Harbour Statement
Safe Harbour Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diff
Slide 3: The Alembic Journey
The Alembic Journey 2003 State-of-the-art 2001 Formulations facility for Starts Regulatory 1972 manufacturing of Markets "Althrocin"- a Cephalosporin C 1971 brand of Erythromycin Erythromycin launched 1961 manufactured for the first Lal Bahadur time in India 1940 Shastri, the then Started Prime mini
Slide 4: The Alembic Journey
The Alembic Journey 2014 - Para IV filed 2011 - Cumulatively - ANVISA 64 ANDAs filed, approvals (35 ANDA/NDA 2010 - Aggressive approved) - Azithral sales ANDAs and and 66 DMFs 2009 Reach INR 1000 million DMFs filing Addressed mark 2007 chronic therapies through - Demerger AL-APL Acquisition of multi
Slide 5: Strategic Advantage
Strategic Advantage Alembic Research Centre is Well-developed the first in India to be Infrastructure facility - Information Security Certified 3 US FDA approved plants Highly talented pool of High-end quality / 350 Research Scientists RA structure R&D / F&D / Captive Manufacturing excellence Bio-eq
Slide 6: Alembic Research Centre
Alembic Research Centre State-of-the-art Analytical & IPR infrastructure R&D FACILITY F&D CAPABILITIES BIO EQUIVALENCE CENTRE R&D Centre has been Expertise in Drug Deliveries State-of-the-art 90-bedded new recognized by DSIR, and Niche Formulations Bio Centre Govt. of India Well-defined Processes Hi
Slide 7: Research Capabilities
Research Capabilities FORMULATIONS API 64 ANDA Filing ANDAs filed 66 60 with DMFs Filing DMFs filed 35 ANDA / NDA approvals 64 61 66 66 57 60 44 54 37 45 25 32 25 32 13 12 13 7 9 4 6 6 3 0 Up to 2010-11 2011-12 2012-13 2013-14 Q1 2014-15 Up to 2010-11 2011-12 2012-13 2013-14 Q1 2014-15 2009-10 2009-
Slide 8: Manufacturing Infrastructure
Manufacturing Infrastructure Formulations - Generics Branded Formulations API (Regulatory Markets) USFDA, MCC, MHRA, Formulations plant at USFDA, EDQM, TGA, WHO ANVISA, TPD approved Baddi, Himachal Pradesh approved API facility at formulations facility at Panelav Panelav and at Karkhadi Current annu
Slide 9: Manufacturing Infrastructure – Certifications
Manufacturing Infrastructure Certifications
Slide 10: Effective Marketing
Effective Marketing PAN India Marketing and Distribution Network OSTEOFIT ZENOVI Orthopedics Gynecology SPECIA Cardiology SUMMIT Diabetes EYECARE Cardiology INTENSA Urology ENTERON Ophthalmology Diabetes Critical Care Gastroenterology ALCARE GASTRON CORAZON Gynecology Gastroenterology RESPIRATORY Ca
Slide 11: Major Product Portfolio
Major Product Portfolio Top Therapatic Ranking* Other Therapatic Products Area Products Area Azithral Anti Infective 38 Rekool Gastroenterology Zeet/Bro-Zeet Cough & Cold Althrocin Anti Infective 61 Tellzy Cardiology Wikoryl Respiratory 161 Rosave Cardiology Sharkoferrol Tonic Roxid Anti Infective 1
Slide 12: Growth Drivers – Branded Formulations
Growth Drivers Branded Formulations Enhanced focus on existing branded business Through effective pan-India distribution Expected network and therapy based marketing annual growth and by pushing ahead acute and chronic segments like anti-infectives and cough 15-18% & cold medications Launch 20-25 ne
Slide 13: Growth Drivers – International Generics
Growth Drivers International Generics Superior cost efficiency Position Alembic as a cost efficient dependable quality manufacturer Expanded annual production capacity Annual production enhanced from 2.6 billion tablets/capsules to 5 billion tablets/capsules. Further being expanded to 7 billion tabl
Slide 14: Financial Highlights – Quarterly
Financial Highlights – Quarterly Consolidated Q I - FY 14-15 INR million Sales Q I / 14-15 Q I / 13-14 Business Share '15 Growth % Formulation India Branded 2,233 1,920 45% 16% India Generics 252 264 5% -5% International Branded 227 150 5% 51% International Generics 1,138 855 23% 33% API 1,063 1,070
Slide 15: Financial Highlights – Quarterly
Financial Highlights – Quarterly Result Highlight (Consolidated) Q I - FY 14-15 INR million Particulars Q I / 14-15 Q I / 13-14 Growth % EBDITA (Before R&D) 1,262 939 34% EBDITA (Post R&D) 967 715 35% EBDITA % 19.5% 16.7% PBT 849 605 40% PAT 647 466 39%
Slide 16: Financial Highlights – 2013-14
Financial Highlights – 2013-14 Consolidated FY 2013-14 INR million Sales 2013-14 2012-13 Business Share '14 Growth % Formulation India Branded 8,506 7,484 46% 14% India Generics 1,207 1,262 6% -4% International Branded 736 558 4% 32% International Generics 4,684 2,358 25% 99% API 3,388 3,505 18% -3%
Slide 17: Financial Highlights – 2013-14
Financial Highlights – 2013-14 Result Highlight (Consolidated) FY 2013-14 INR million Particulars 2013-14 2012-13 Growth % EBDITA (Before R&D) 4,741 45% 3,263 EBDITA (Post R&D) 3,577 2,520 42% EBDITA % 19.2% 16.5% PBT 3,106 2,064 51% PAT 2,355 1,653 43%
Slide 18: Revenue Overview
Revenue Overview Sales Composition Q1 FY 14-15 API Export Export Incentive 15% 1% API Domestic 6% India Branded Formulations International Generics 45% 23% International Branded Formulation India Generics 5% 5%
Slide 19: Revenue Overview
Revenue Overview Sales Composition Q1 FY 14-15 Therapy Based Sales Break up Business Anti Infectives 31% Cough & Cold 10% General 41% Domestic Domestic Branded Branded Gastrology 21% Business Business Cardiology 12% Gynecology 11% Orthopedics 5% Anti Diabetic 6% Nephrology/Urology 2% Ophthalmology 2
Slide 20: Revenue Overview
Revenue Overview Sales Composition FY 13-14 API Export Export Incentive 15% 1% API Domestic 3% India Branded Formulations International Generics 46% 25% International Branded Formulation India Generics 4% 6%
Slide 21: R & D Expense
R & D Expense Increased Thrust on Research to create Intellectual Property R&D spend as a % to Sales 7.00% 6.04% 5.06% 4.78% 4.06% 2010-11 2011-12 2012-13 2013-14 Q1 2014-15
Slide 22: Shareholding Pattern
Shareholding Pattern Alembic Pharmaceuticals Limited Promoter Group 45% Alembic Limited Public 29% 15% FI / FII / MF Total Paid up Capital 11% INR 377.03 million 188.52 million Total No. of Shareholders 49,555 Market Capitalisation INR 50,193 million As on 30th June 2014
Slide 23: Corporate Social Responsibility
Corporate Social Responsibility Rural Development Society Rural Development Society is a Social Responsibility Initiative of Alembic founded in 1979 Enhancement for self employment and income generation for economic development School, hostel and medical facilities for local villagers
Slide 24: Corporate Social Responsibility
Corporate Social Responsibility Environment Alembic believes in clean and green chemistry Zero discharge facilities comprising of state-of-the-art aeration system, ultra filtration and reverse osmosis plant, evaporation and incineration plant Dedicated scrubbing system for process gas emissions
Slide 25: Alembic Pharmaceuticals Limited
For updates and specific queries please visit : www.alembic-india.com or feel free to contact : Ajay Kumar Desai Mitanshu Shah Tel.: 022- 306 11681 • Fax: 022 – 306 11682 Tel.: 0265 - 300 7630 • Fax: 0265 - 228 2506 [email protected] [email protected] Alembic Pharmaceuticals Limited
Slide 26: Thank You
Alembicy, Thank You
Alembic Pharmaceuticals — Q1 2014-15 Earnings Presentation on 6ix